Search

Your search keyword '"Abida, Wassim"' showing total 489 results
Start Over Author "Abida, Wassim"
489 results on '"Abida, Wassim"'

51. Supplementary Figure from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

52. Supplementary Tables 1-6 and Supplementary Figures 1-6 from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Wibmer, Andreas G., primary, Haywood, Samuel, primary, Weg, Emily S., primary, Barnett, Ethan S., primary, Kim, Chloe J., primary, Carbone, Emily A., primary, Vasselman, Samantha E., primary, Nguyen, Bastien, primary, Hullings, Melanie A., primary, Scher, Howard I., primary, Morris, Michael J., primary, Solit, David B., primary, Schultz, Nikolaus, primary, Kantoff, Philip W., primary, and Abida, Wassim, primary

Published
2023
Full Text
View/download PDF

53. Supplementary Table 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

54. Supplementary Data from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Wibmer, Andreas G., primary, Haywood, Samuel, primary, Weg, Emily S., primary, Barnett, Ethan S., primary, Kim, Chloe J., primary, Carbone, Emily A., primary, Vasselman, Samantha E., primary, Nguyen, Bastien, primary, Hullings, Melanie A., primary, Scher, Howard I., primary, Morris, Michael J., primary, Solit, David B., primary, Schultz, Nikolaus, primary, Kantoff, Philip W., primary, and Abida, Wassim, primary

Published
2023
Full Text
View/download PDF

55. Supplementary Figure 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

56. Supplementary Figure 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

57. Supplementary Table S8-S12 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Author

Kim, Dae-Hwan, primary, Sun, Duanchen, primary, Storck, William K., primary, Welker Leng, Katherine, primary, Jenkins, Chelsea, primary, Coleman, Daniel J., primary, Sampson, David, primary, Guan, Xiangnan, primary, Kumaraswamy, Anbarasu, primary, Rodansky, Eva S., primary, Urrutia, Joshua A., primary, Schwartzman, Jacob A., primary, Zhang, Chao, primary, Beltran, Himisha, primary, Labrecque, Mark P., primary, Morrissey, Colm, primary, Lucas, Jared M., primary, Coleman, Ilsa M., primary, Nelson, Peter S., primary, Corey, Eva, primary, Handelman, Samuel K., primary, Sexton, Jonathan Z., primary, Aggarwal, Rahul, primary, Abida, Wassim, primary, Feng, Felix Y., primary, Small, Eric J., primary, Spratt, Daniel E., primary, Bankhead, Armand, primary, Rao, Arvind, primary, Gesner, Emily M., primary, Attwell, Sarah, primary, Lakhotia, Sanjay, primary, Campeau, Eric, primary, Yates, Joel A., primary, Xia, Zheng, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

58. Table S4 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

Author

Tukachinsky, Hanna, primary, Madison, Russell W., primary, Chung, Jon H., primary, Gjoerup, Ole V., primary, Severson, Eric A., primary, Dennis, Lucas, primary, Fendler, Bernard J., primary, Morley, Samantha, primary, Zhong, Lei, primary, Graf, Ryon P., primary, Ross, Jeffrey S., primary, Alexander, Brian M., primary, Abida, Wassim, primary, Chowdhury, Simon, primary, Ryan, Charles J., primary, Fizazi, Karim, primary, Golsorkhi, Tony, primary, Watkins, Simon P., primary, Simmons, Andrew, primary, Loehr, Andrea, primary, Venstrom, Jeffrey M., primary, and Oxnard, Geoffrey R., primary

Published
2023
Full Text
View/download PDF

59. Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

60. Supplementary Table S2 S4 S6 S7 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Author

Kim, Dae-Hwan, primary, Sun, Duanchen, primary, Storck, William K., primary, Welker Leng, Katherine, primary, Jenkins, Chelsea, primary, Coleman, Daniel J., primary, Sampson, David, primary, Guan, Xiangnan, primary, Kumaraswamy, Anbarasu, primary, Rodansky, Eva S., primary, Urrutia, Joshua A., primary, Schwartzman, Jacob A., primary, Zhang, Chao, primary, Beltran, Himisha, primary, Labrecque, Mark P., primary, Morrissey, Colm, primary, Lucas, Jared M., primary, Coleman, Ilsa M., primary, Nelson, Peter S., primary, Corey, Eva, primary, Handelman, Samuel K., primary, Sexton, Jonathan Z., primary, Aggarwal, Rahul, primary, Abida, Wassim, primary, Feng, Felix Y., primary, Small, Eric J., primary, Spratt, Daniel E., primary, Bankhead, Armand, primary, Rao, Arvind, primary, Gesner, Emily M., primary, Attwell, Sarah, primary, Lakhotia, Sanjay, primary, Campeau, Eric, primary, Yates, Joel A., primary, Xia, Zheng, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

65. The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Author

Chakraborty, Goutam, Nandakumar, Subhiksha, Hirani, Rahim, Nguyen, Bastien, Stopsack, Konrad H, Kreitzer, Christoph, Rajanala, Sai Harisha, Ghale, Romina, Mazzu, Ying Z, Pillarsetty, Naga Vara Kishore, Lee, Gwo-Shu Mary, Scher, Howard I, Morris, Michael J, Traina, Tiffany, Razavi, Pedram, Abida, Wassim, Durack, Jeremy C, Solomon, Stephen B, Vander Heiden, Matthew G, Mucci, Lorelei A, Wibmer, Andreas G, Schultz, Nikolaus, Kantoff, Philip W, Chakraborty, Goutam, Nandakumar, Subhiksha, Hirani, Rahim, Nguyen, Bastien, Stopsack, Konrad H, Kreitzer, Christoph, Rajanala, Sai Harisha, Ghale, Romina, Mazzu, Ying Z, Pillarsetty, Naga Vara Kishore, Lee, Gwo-Shu Mary, Scher, Howard I, Morris, Michael J, Traina, Tiffany, Razavi, Pedram, Abida, Wassim, Durack, Jeremy C, Solomon, Stephen B, Vander Heiden, Matthew G, Mucci, Lorelei A, Wibmer, Andreas G, Schultz, Nikolaus, and Kantoff, Philip W

Abstract

Abstract Purpose: Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate cancer is largely unknown. Experimental Design: Patients in this study underwent tumor sequencing using the MSK-IMPACT clinical assay to capture single-nucleotide variants, insertions, and deletions; copy-number alterations; and structural rearrangements, or were profiled through The Cancer Genome Atlas. The association between PIK3R1 alteration/expression and survival was evaluated using univariable and multivariable Cox proportional-hazards regression models. We used the siRNA-based knockdown of PIK3R1 for functional studies. FDG-PET/CT examinations were performed with a hybrid positron emission tomography (PET)/CT scanner for some prostate cancer patients in the MSK-IMPACT cohort. Results: Analyzing 1,417 human prostate cancers, we found a significant enrichment of PIK3R1 alterations in metastatic cancers compared with primary cancers. PIK3R1 alterations or reduced mRNA expression tended to be associated with worse clinical outcomes in prostate cancer, particularly in primary disease, as well as in breast, gastric, and several other cancers. In prostate cancer cell lines, PIK3R1 knockdown resulted in increased cell proliferation and AKT activity, including insulin-stimulated AKT activity. In cell lines and organoids, PIK3R1 loss/mutation was associated with increased sensitivity to AKT inhibitors. PIK3R1-altered patient prostate tumors had increased uptake of the glucose analogue 18F-fluorodeoxyglucose in PET imaging, suggesting increased glycolysis. Conclusions: Our

Published
2023

66. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration:Final Results from the Phase 2 TRITON2 Study

Author

Abida, Wassim, Campbell, David, Patnaik, Akash, Bryce, Alan H., Shapiro, Jeremy, Bambury, Richard M., Zhang, Jingsong, Burke, John M., Castellano, Daniel, Font, Albert, Ganju, Vinod, Hardy-Bessard, Anne Claire, McDermott, Ray, Sautois, Brieuc, Spaeth, Dominique, Voog, Eric, Piulats, Josep M., Pintus, Elias, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Loehr, Andrea, Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Go, Jowell, Watkins, Simon P., Chowdhury, Simon, Abida, Wassim, Campbell, David, Patnaik, Akash, Bryce, Alan H., Shapiro, Jeremy, Bambury, Richard M., Zhang, Jingsong, Burke, John M., Castellano, Daniel, Font, Albert, Ganju, Vinod, Hardy-Bessard, Anne Claire, McDermott, Ray, Sautois, Brieuc, Spaeth, Dominique, Voog, Eric, Piulats, Josep M., Pintus, Elias, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Loehr, Andrea, Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Go, Jowell, Watkins, Simon P., and Chowdhury, Simon

Abstract

Background: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other DNA damage repair (DDR) gene alteration. Objective: To present the final data from TRITON2. Design, setting, and participants: TRITON2 enrolled patients with mCRPC who had progressed on one or two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy. Outcome measurements and statistical analysis: The primary endpoint was objective response rate (ORR; as per the modified Response Evaluation Criteria in Solid Tumor Version 1.1/Prostate Cancer Clinical Trials Working Group 3 criteria in patients with measurable disease by independent radiology review [IRR]); prostate-specific antigen (PSA) response rate (≥50% decrease from baseline [PSA50]) was a key secondary endpoint. Results and limitations: As of July 27, 2021 (study closure), TRITON2 had enrolled 277 patients, grouped by mutated gene: BRCA (n = 172), ATM (n = 59), CDK12 (n = 15), CHEK2 (n = 7), PALB2 (n = 11), or other DDR gene (Other; n = 13). ORR by IRR was 46% (37/81) in the BRCA subgroup (95% confidence interval [CI], 35–57%), 100% (4/4) in the PALB2 subgroup (95% CI, 40–100%), and 25% (3/12) in the Other subgroup (95% CI, 5.5–57%). No patients within the ATM, CDK12, or CHEK2 subgroups had an objective response by IRR. PSA50 response rates (95% CI) in the BRCA, PALB2, ATM, CDK12, CHEK2, and Other subgroups were 53% (46–61%), 55% (23–83%), 3.4% (0.4–12), 6.7% (0.2–32%), 14% (0.4–58%), and 23% (5.0–54%), respectively. Conclusions: The final TRITON2 results confirm the clinical benefit and manageable safety profile of rucaparib in patients with mCRPC, including those with an alteration in BRCA or select non-BRCA DDR gene. Patient summary: Almost half of TRITON2 patients with BRCA-mutated metastatic castration-resistant prostate cancer had a complete or

Published
2023

67. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)

Author

Armstrong, Andrew J., Taylor, Amy, Haffner, Michael C., Abida, Wassim, Bryce, Alan H., Karsh, Lawrence I., Tagawa, Scott T., Twardowski, Przemyslaw, Serritella, Anthony V., and Lang, Joshua M.

Abstract

Background/Objectives: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. Subjects/Methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023–2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. Results/Conclusion: We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.

Published
2024
Full Text
View/download PDF

68. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Author

Fizazi, Karim, primary, Piulats, Josep M., additional, Reaume, M. Neil, additional, Ostler, Peter, additional, McDermott, Ray, additional, Gingerich, Joel R., additional, Pintus, Elias, additional, Sridhar, Srikala S., additional, Bambury, Richard M., additional, Emmenegger, Urban, additional, Lindberg, Henriette, additional, Morris, David, additional, Nolè, Franco, additional, Staffurth, John, additional, Redfern, Charles, additional, Sáez, María I., additional, Abida, Wassim, additional, Daugaard, Gedske, additional, Heidenreich, Axel, additional, Krieger, Laurence, additional, Sautois, Brieuc, additional, Loehr, Andrea, additional, Despain, Darrin, additional, Heyes, Catherine A., additional, Watkins, Simon P., additional, Chowdhury, Simon, additional, Ryan, Charles J., additional, and Bryce, Alan H., additional

Published
2023
Full Text
View/download PDF

69. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.

Author

Bryce, Alan Haruo, primary, Piulats, Josep M., additional, Reaume, M. Neil, additional, Ostler, Peter James, additional, McDermott, Raymond S., additional, Gingerich, Joel Roger, additional, Pintus, Elias, additional, Sridhar, Srikala S., additional, Abida, Wassim, additional, Daugaard, Gedske, additional, Heidenreich, Axel, additional, Krieger, Laurence E. M., additional, Sautois, Brieuc, additional, Loehr, Andrea, additional, Despain, Darrin, additional, Go, Jowell, additional, Watkins, Simon Paul, additional, Chowdhury, Simon, additional, Ryan, Charles J., additional, and Fizazi, Karim, additional

Published
2023
Full Text
View/download PDF

70. Abstract B026: Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets

Author

Tang, Fanying, primary, Xu, Duo, additional, Wang, Shangqian, additional, Wong, Chen Khuan, additional, Martinez-Fundichely, Alexander, additional, Lee, Cindy, additional, Cohen, Sandra, additional, Park, Jane, additional, Hill, Corinne, additional, Eng, Kenneth, additional, Bareja, Rohan, additional, Han, Teng, additional, Liu, Eric Minwei, additional, Palladino, Ann, additional, Di, Wei, additional, Gao, Dong, additional, Abida, Wassim, additional, Beg, Shaham, additional, Puca, Loredana, additional, Meneses, Maximiliano, additional, De Stanchina, Elisa, additional, Berger, Michael, additional, Gopalan, Anuradha, additional, Dow, Lukas, additional, Mosquera, Juan Miguel, additional, Beltran, Himisha, additional, Sternberg, Cora, additional, Chi, Ping, additional, Scher, Howard, additional, Sboner, Andrea, additional, Chen, Yu, additional, and Khurana, Ekta, additional

Published
2022
Full Text
View/download PDF

71. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Author

Zehir, Ahmet, Benayed, Ryma, Shah, Ronak H, Syed, Aijazuddin, Middha, Sumit, Kim, Hyunjae R, Srinivasan, Preethi, Gao, Jianjiong, Chakravarty, Debyani, Devlin, Sean M, Hellmann, Matthew D, Barron, David A, Schram, Alison M, Hameed, Meera, Dogan, Snjezana, Ross, Dara S, Hechtman, Jaclyn F, DeLair, Deborah F, Yao, JinJuan, Mandelker, Diana L, Cheng, Donavan T, Chandramohan, Raghu, Mohanty, Abhinita S, Ptashkin, Ryan N, Jayakumaran, Gowtham, Prasad, Meera, Syed, Mustafa H, Rema, Anoop Balakrishnan, Liu, Zhen Y, Nafa, Khedoudja, Borsu, Laetitia, Sadowska, Justyna, Casanova, Jacklyn, Bacares, Ruben, Kiecka, Iwona J, Razumova, Anna, Son, Julie B, Stewart, Lisa, Baldi, Tessara, Mullaney, Kerry A, Al-Ahmadie, Hikmat, Vakiani, Efsevia, Abeshouse, Adam A, Penson, Alexander V, Jonsson, Philip, Camacho, Niedzica, Chang, Matthew T, Won, Helen H, Gross, Benjamin E, Kundra, Ritika, Heins, Zachary J, Chen, Hsiao-Wei, Phillips, Sarah, Zhang, Hongxin, Wang, Jiaojiao, Ochoa, Angelica, Wills, Jonathan, Eubank, Michael, Thomas, Stacy B, Gardos, Stuart M, Reales, Dalicia N, Galle, Jesse, Durany, Robert, Cambria, Roy, Abida, Wassim, Cercek, Andrea, Feldman, Darren R, Gounder, Mrinal M, Hakimi, A Ari, Harding, James J, Iyer, Gopa, Janjigian, Yelena Y, Jordan, Emmet J, Kelly, Ciara M, Lowery, Maeve A, Morris, Luc G T, Omuro, Antonio M, Raj, Nitya, Razavi, Pedram, Shoushtari, Alexander N, Shukla, Neerav, Soumerai, Tara E, Varghese, Anna M, Yaeger, Rona, Coleman, Jonathan, Bochner, Bernard, Riely, Gregory J, Saltz, Leonard B, Scher, Howard I, Sabbatini, Paul J, Robson, Mark E, Klimstra, David S, Taylor, Barry S, Baselga, Jose, Schultz, Nikolaus, Hyman, David M, Arcila, Maria E, Solit, David B, Ladanyi, Marc, and Berger, Michael F

Subjects
Cancer -- Genetic aspects -- Research, Gene mutation -- Research, Cancer metastasis -- Genetic aspects -- Development and progression, Biological sciences, Health
Abstract

Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible., Author(s): Ahmet Zehir [1]; Ryma Benayed [1]; Ronak H Shah [1]; Aijazuddin Syed [1]; Sumit Middha [1]; Hyunjae R Kim [1]; Preethi Srinivasan [1]; Jianjiong Gao [2]; Debyani Chakravarty [2]; [...]

Published
2017
Full Text
View/download PDF

72. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Author

Smyth, Lillian M., Monson, Kelsey R., Jhaveri, Komal, Drilon, Alexander, Li, Bob T., Abida, Wassim, Iyer, Gopa, Gerecitano, John F., Gounder, Mrinal, Harding, James J., Voss, Martin H., Makker, Vicky, Ho, Alan L., Razavi, Pedram, Iasonos, Alexia, Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Erinjeri, Joseph P., Katabi, Nora, Fury, Matthew G., and Hyman, David M.

Published
2017
Full Text
View/download PDF

73. Author Correction: Tumour lineage shapes BRCA-mediated phenotypes

Author

Jonsson, Philip, Bandlamudi, Chaitanya, Cheng, Michael L., Srinivasan, Preethi, Chavan, Shweta S., Friedman, Noah D., Rosen, Ezra Y., Richards, Allison L., Bouvier, Nancy, Selcuklu, S. Duygu, Bielski, Craig M., Abida, Wassim, Mandelker, Diana, Birsoy, Ozge, Zhang, Liying, Zehir, Ahmet, Donoghue, Mark T. A., Baselga, José, Offit, Kenneth, Scher, Howard I., O’Reilly, Eileen M., Stadler, Zsofia K., Schultz, Nikolaus, Socci, Nicholas D., Viale, Agnes, Ladanyi, Marc, Robson, Mark E., Hyman, David M., Berger, Michael F., Solit, David B., and Taylor, Barry S.

Published
2020
Full Text
View/download PDF

74. AML-743 Germline Homologous Recombination Deficiency (HRD) Influences the Fitness Impact of Oncologic Therapy on DNA Damage Response Gene Clonal Hematopoiesis (CH)

Author

Baeten, Jeremy T., Chan, Irenaeus C.C., Moukarzel, Lea, Carter, Amber C., Patel, Minal, Stopsack, Konrad, Pharoah, Paul, Brenton, James, Li, Bob, Abida, Wassim, Schram, Alison, Cadoo, Karen, Weigelt, Britta, Cruchaga, Carlos, Scher, Howard, Levine, Ross, Papaemmanuil, Elli, Link, Daniel C., and Bolton, Kelly L.

Published
2024
Full Text
View/download PDF

75. Germline Homologous Recombination Deficiency (HRD) Influences the Fitness Impact of Oncologic Therapy on DNA Damage Response Gene Clonal Hematopoiesis (CH)

Author

Baeten, Jeremy T., Chan, Irenaeus C.C., Moukarzel, Lea, Carter, Amber C., Patel, Minal, Stopsack, Konrad, Pharoah, Paul, Brenton, James, Li, Bob, Abida, Wassim, Schram, Alison, Cadoo, Karen, Weigelt, Britta, Cruchaga, Carlos, Scher, Howard, Levine, Ross, Papaemmanuil, Elli, Link, Daniel C., and Bolton, Kelly L.

Published
2024
Full Text
View/download PDF

78. The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

Author

Chakraborty, Goutam, primary, Nandakumar, Subhiksha, additional, Hirani, Rahim, additional, Nguyen, Bastien, additional, Stopsack, Konrad H., additional, Kreitzer, Christoph, additional, Rajanala, Sai Harisha, additional, Ghale, Romina, additional, Mazzu, Ying Z., additional, Pillarsetty, Naga Vara Kishore, additional, Lee, Gwo-Shu Mary, additional, Scher, Howard I., additional, Morris, Michael J., additional, Traina, Tiffany, additional, Razavi, Pedram, additional, Abida, Wassim, additional, Durack, Jeremy C., additional, Solomon, Stephen B., additional, Vander Heiden, Matthew G., additional, Mucci, Lorelei A., additional, Wibmer, Andreas G., additional, Schultz, Nikolaus, additional, and Kantoff, Philip W., additional

Published
2022
Full Text
View/download PDF

80. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

Author

Mandelker, Diana, Zhang, Liying, Kemel, Yelena, Stadler, Zsofia K., Joseph, Vijai, Zehir, Ahmet, Pradhan, Nisha, Arnold, Angela, Walsh, Michael F., Li, Yirong, Balakrishnan, Anoop R., Syed, Aijazuddin, Prasad, Meera, Nafa, Khedoudja, Carlo, Maria I., Cadoo, Karen A., Sheehan, Meg, Fleischut, Megan H., Salo-Mullen, Erin, Trottier, Magan, Lipkin, Steven M., Lincoln, Anne, Mukherjee, Semanti, Ravichandran, Vignesh, Cambria, Roy, Galle, Jesse, Abida, Wassim, Arcila, Marcia E., Benayed, Ryma, Shah, Ronak, Yu, Kenneth, Bajorin, Dean F., Coleman, Jonathan A., Leach, Steven D., Lowery, Maeve A., Garcia-Aguilar, Julio, Kantoff, Philip W., Sawyers, Charles L., Dickler, Maura N., Saltz, Leonard, Motzer, Robert J., O’Reilly, Eileen M., Scher, Howard I., Baselga, Jose, Klimstra, David S., Solit, David B., Hyman, David M., Berger, Michael F., Ladanyi, Marc, Robson, Mark E., and Offit, Kenneth

Published
2017
Full Text
View/download PDF

81. CANCER THERAPY: SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer

Author

Mu, Ping, Zhang, Zeda, Benelli, Matteo, Karthaus, Wouter R., Hoover, Elizabeth, Chen, Chi-Chao, Wongvipat, John, Ku, Sheng-Yu, Gao, Dong, Cao, Zhen, Shah, Neel, Adams, Elizabeth J., Abida, Wassim, Watson, Philip A., Prandi, Davide, Huang, Chun-Hao, de Stanchina, Elisa, Lowe, Scott W., Ellis, Leigh, Beltran, Himisha, Rubin, Mark A., Goodrich, David W., Demichelis, Francesca, and Sawyers, Charles L.

Published
2017
Full Text
View/download PDF

82. Publisher Correction: The long tail of oncogenic drivers in prostate cancer

Author

Armenia, Joshua, Wankowicz, Stephanie A. M., Liu, David, Gao, Jianjiong, Kundra, Ritika, Reznik, Ed, Chatila, Walid K., Chakravarty, Debyani, Han, G. Celine, Coleman, Ilsa, Montgomery, Bruce, Pritchard, Colin, Morrissey, Colm, Barbieri, Christopher E., Beltran, Himisha, Sboner, Andrea, Zafeiriou, Zafeiris, Miranda, Susana, Bielski, Craig M., Penson, Alexander V., Tolonen, Charlotte, Huang, Franklin W., Robinson, Dan, Wu, Yi Mi, Lonigro, Robert, Garraway, Levi A., Demichelis, Francesca, Kantoff, Philip W., Taplin, Mary-Ellen, Abida, Wassim, Taylor, Barry S., Scher, Howard I., Nelson, Peter S., de Bono, Johann S., Rubin, Mark A., Sawyers, Charles L., Chinnaiyan, Arul M., PCF/SU2C International Prostate Cancer Dream Team, Schultz, Nikolaus, and Van Allen, Eliezer M.

Published
2019
Full Text
View/download PDF

83. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets

Author

Tang, Fanying, primary, Xu, Duo, additional, Wang, Shangqian, additional, Wong, Chen Khuan, additional, Martinez-Fundichely, Alexander, additional, Lee, Cindy J., additional, Cohen, Sandra, additional, Park, Jane, additional, Hill, Corinne E., additional, Eng, Kenneth, additional, Bareja, Rohan, additional, Han, Teng, additional, Liu, Eric Minwei, additional, Palladino, Ann, additional, Di, Wei, additional, Gao, Dong, additional, Abida, Wassim, additional, Beg, Shaham, additional, Puca, Loredana, additional, Meneses, Maximiliano, additional, de Stanchina, Elisa, additional, Berger, Michael F., additional, Gopalan, Anuradha, additional, Dow, Lukas E., additional, Mosquera, Juan Miguel, additional, Beltran, Himisha, additional, Sternberg, Cora N., additional, Chi, Ping, additional, Scher, Howard I., additional, Sboner, Andrea, additional, Chen, Yu, additional, and Khurana, Ekta, additional

Published
2022
Full Text
View/download PDF

84. Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality

Author

Keegan, Niamh M., primary, Vasselman, Samantha E., additional, Barnett, Ethan S., additional, Nweji, Barbara, additional, Carbone, Emily A., additional, Blum, Alexander, additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Scher, Howard I., additional, Kantoff, Philip W., additional, Abida, Wassim, additional, and Stopsack, Konrad H., additional

Published
2022
Full Text
View/download PDF

85. Inherited TP53 Variants and Risk of Prostate Cancer

Author

Maxwell, Kara N., primary, Cheng, Heather H., additional, Powers, Jacquelyn, additional, Gulati, Roman, additional, Ledet, Elisa M., additional, Morrison, Casey, additional, Le, Anh, additional, Hausler, Ryan, additional, Stopfer, Jill, additional, Hyman, Sophie, additional, Kohlmann, Wendy, additional, Naumer, Anne, additional, Vagher, Jennie, additional, Greenberg, Samantha E., additional, Naylor, Lorraine, additional, Laurino, Mercy, additional, Konnick, Eric Q., additional, Shirts, Brian H., additional, AlDubayan, Saud H., additional, Van Allen, Eliezer M., additional, Nguyen, Bastien, additional, Vijai, Joseph, additional, Abida, Wassim, additional, Carlo, Maria I., additional, Dubard-Gault, Marianne, additional, Lee, Daniel J., additional, Maese, Luke D., additional, Mandelker, Diana, additional, Montgomery, Bruce, additional, Morris, Michael J., additional, Nicolosi, Piper, additional, Nussbaum, Robert L., additional, Schwartz, Lauren E., additional, Stadler, Zsofia, additional, Garber, Judy E., additional, Offit, Kenneth, additional, Schiffman, Joshua D., additional, Nelson, Peter S., additional, Sartor, Oliver, additional, Walsh, Michael F., additional, and Pritchard, Colin C., additional

Published
2022
Full Text
View/download PDF

86. Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI).

Author

Alva, Ajjai Shivaram, primary, Li, Jinju, additional, Chou, Jonathan, additional, Reimers, Melissa Andrea, additional, McKay, Rana R., additional, Zhang, Jingsong, additional, Daignault-Newton, Stephanie, additional, Palmbos, Phillip Lee, additional, Reichert, Zachery R, additional, Cieslik, Marcin, additional, Chinnaiyan, Arul, additional, and Abida, Wassim, additional

Published
2022
Full Text
View/download PDF

88. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Author

Nguyen, Bastien, primary, Fong, Christopher, additional, Luthra, Anisha, additional, Smith, Shaleigh A., additional, DiNatale, Renzo G., additional, Nandakumar, Subhiksha, additional, Walch, Henry, additional, Chatila, Walid K., additional, Madupuri, Ramyasree, additional, Kundra, Ritika, additional, Bielski, Craig M., additional, Mastrogiacomo, Brooke, additional, Donoghue, Mark T.A., additional, Boire, Adrienne, additional, Chandarlapaty, Sarat, additional, Ganesh, Karuna, additional, Harding, James J., additional, Iacobuzio-Donahue, Christine A., additional, Razavi, Pedram, additional, Reznik, Ed, additional, Rudin, Charles M., additional, Zamarin, Dmitriy, additional, Abida, Wassim, additional, Abou-Alfa, Ghassan K., additional, Aghajanian, Carol, additional, Cercek, Andrea, additional, Chi, Ping, additional, Feldman, Darren, additional, Ho, Alan L., additional, Iyer, Gopakumar, additional, Janjigian, Yelena Y., additional, Morris, Michael, additional, Motzer, Robert J., additional, O’Reilly, Eileen M., additional, Postow, Michael A., additional, Raj, Nitya P., additional, Riely, Gregory J., additional, Robson, Mark E., additional, Rosenberg, Jonathan E., additional, Safonov, Anton, additional, Shoushtari, Alexander N., additional, Tap, William, additional, Teo, Min Yuen, additional, Varghese, Anna M., additional, Voss, Martin, additional, Yaeger, Rona, additional, Zauderer, Marjorie G., additional, Abu-Rustum, Nadeem, additional, Garcia-Aguilar, Julio, additional, Bochner, Bernard, additional, Hakimi, Abraham, additional, Jarnagin, William R., additional, Jones, David R., additional, Molena, Daniela, additional, Morris, Luc, additional, Rios-Doria, Eric, additional, Russo, Paul, additional, Singer, Samuel, additional, Strong, Vivian E., additional, Chakravarty, Debyani, additional, Ellenson, Lora H., additional, Gopalan, Anuradha, additional, Reis-Filho, Jorge S., additional, Weigelt, Britta, additional, Ladanyi, Marc, additional, Gonen, Mithat, additional, Shah, Sohrab P., additional, Massague, Joan, additional, Gao, Jianjiong, additional, Zehir, Ahmet, additional, Berger, Michael F., additional, Solit, David B., additional, Bakhoum, Samuel F., additional, Sanchez-Vega, Francisco, additional, and Schultz, Nikolaus, additional

Published
2022
Full Text
View/download PDF

89. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Author

Loehr, Andrea, primary, Patnaik, Akash, additional, Campbell, David, additional, Shapiro, Jeremy, additional, Bryce, Alan H., additional, McDermott, Ray, additional, Sautois, Brieuc, additional, Vogelzang, Nicholas J., additional, Bambury, Richard M., additional, Voog, Eric, additional, Zhang, Jingsong, additional, Piulats, Josep M., additional, Hussain, Arif, additional, Ryan, Charles J., additional, Merseburger, Axel S., additional, Daugaard, Gedske, additional, Heidenreich, Axel, additional, Fizazi, Karim, additional, Higano, Celestia S., additional, Krieger, Laurence E., additional, Sternberg, Cora N., additional, Watkins, Simon P., additional, Despain, Darrin, additional, Simmons, Andrew D., additional, Dowson, Melanie, additional, Golsorkhi, Tony, additional, Chowdhury, Simon, additional, and Abida, Wassim, additional

Published
2021
Full Text
View/download PDF

90. Abstract P041: Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer

Author

Abida, Wassim, primary, Agarwal, Neeraj, additional, Hahn, Andrew W., additional, Shore, Neal, additional, Sieber, Paul, additional, Dorff, Tanya, additional, Rettig, Mathew, additional, Smith, Mathew, additional, Monk, Paul, additional, Xu, Rongda, additional, Johnson, Ann, additional, Daemen, Anneleen, additional, Maneval, Edna Chow, additional, Multani, Pratik S., additional, Patel, Rupal, additional, and Morris, Michael J., additional

Published
2021
Full Text
View/download PDF

91. Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, additional, Arora, Kanika, additional, Nguyen, Bastien, additional, Vasselman, Samantha E., additional, Nweji, Barbara, additional, McBride, Sean M., additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Scher, Howard I., additional, Mucci, Lorelei A., additional, Solit, David B., additional, Gönen, Mithat, additional, Chen, Yu, additional, Berger, Michael F., additional, Schultz, Nikolaus, additional, Abida, Wassim, additional, and Kantoff, Philip W., additional

Published
2021
Full Text
View/download PDF

92. Clinical Annotations for Prostate Cancer Research: Defining Data Elements, Creating a Reproducible Analytical Pipeline, and Assessing Data Quality

Author

Keegan, Niamh M., primary, Vasselman, Samantha E., additional, Barnett, Ethan S., additional, Nweji, Barbara, additional, Carbone, Emily A., additional, Blum, Alexander, additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Kantoff, Philip W., additional, Abida, Wassim, additional, and Stopsack, Konrad H., additional

Published
2021
Full Text
View/download PDF

93. PD44-01 WHEN SHOULD PROSTATE CANCER TUMOR SEQUENCING PROMPT CONSIDERATION FOR GERMLINE TESTING?

Author

Truong, Hong, primary, Breen, Kelsey, additional, Kemel, Yelena, additional, Lenis, Andrew, additional, Reisz, Peter, additional, Benfante, Nicole, additional, Ehdaie, Behfar, additional, Touijer, Karim, additional, Laudone, Vincent, additional, Eastham, James, additional, Joseph, Vijai, additional, Birsoy, Ozge, additional, Mandelker, Diana, additional, Stadler, Zsofia, additional, Offit, Kenneth, additional, Morris, Michael, additional, Abida, Wassim, additional, Robson, Mark, additional, and Carlo, Maria, additional

Published
2021
Full Text
View/download PDF

94. MP24-01 RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER

Author

Lenis, Andrew T., primary, Ravichandran, Vignesh, additional, Truong, Hong, additional, Reisz, Peter, additional, Nweji, Barbara, additional, Autio, Karen, additional, Morris, Michael, additional, Slovin, Susan, additional, Vargas, Hebert Alberto, additional, Laudone, Vincent, additional, Ehdaie, Behfar, additional, Reuter, Victor, additional, Viale, Agnes, additional, Schultz, Nikolaus, additional, Gopalan, Anuradha, additional, Donoghue, Mark, additional, Stopsack, Konrad, additional, Solit, David, additional, and Abida, Wassim, additional

Published
2021
Full Text
View/download PDF

95. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Author

Stadler, Zsofia K., primary, Maio, Anna, additional, Chakravarty, Debyani, additional, Kemel, Yelena, additional, Sheehan, Margaret, additional, Salo-Mullen, Erin, additional, Tkachuk, Kaitlyn, additional, Fong, Christopher J., additional, Nguyen, Bastien, additional, Erakky, Amanda, additional, Cadoo, Karen, additional, Liu, Ying, additional, Carlo, Maria I., additional, Latham, Alicia, additional, Zhang, Hongxin, additional, Kundra, Ritika, additional, Smith, Shaleigh, additional, Galle, Jesse, additional, Aghajanian, Carol, additional, Abu-Rustum, Nadeem, additional, Varghese, Anna, additional, O'Reilly, Eileen M., additional, Morris, Michael, additional, Abida, Wassim, additional, Walsh, Michael, additional, Drilon, Alexander, additional, Jayakumaran, Gowtham, additional, Zehir, Ahmet, additional, Ladanyi, Marc, additional, Ceyhan-Birsoy, Ozge, additional, Solit, David B., additional, Schultz, Nikolaus, additional, Berger, Michael F., additional, Mandelker, Diana, additional, Diaz, Luis A., additional, Offit, Kenneth, additional, and Robson, Mark E., additional

Published
2021
Full Text
View/download PDF

96. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Author

Nguyen, Bastien, primary, Fong, Christopher, additional, Luthra, Anisha, additional, Smith, Shaleigh A., additional, DiNatale, Renzo G., additional, Nandakumar, Subhiksha, additional, Walch, Henry, additional, Chatila, Walid K., additional, Madupuri, Ramyasree, additional, Kundra, Ritika, additional, Bielski, Craig M., additional, Mastrogiacomo, Brooke, additional, Boire, Adrienne, additional, Chandarlapaty, Sarat, additional, Ganesh, Karuna, additional, Harding, James J., additional, lacobuzio-Donahue, Christine A., additional, Razavi, Pedram, additional, Reznik, Ed, additional, Rudin, Charles M., additional, Zamarin, Dmitriy, additional, Abida, Wassim, additional, Abou-Alfa, Ghassan K., additional, Aghajanian, Carol, additional, Cercek, Andrea, additional, Chi, Ping, additional, Feldman, Darren, additional, Ho, Alan L., additional, Iyer, Gopakumar, additional, Janjigian, Yelena Y., additional, Morris, Michael, additional, Motzer, Robert J., additional, O’Reilly, Eileen M., additional, Postow, Michael A., additional, Raj, Nitya P., additional, Riely, Gregory J., additional, Robson, Mark E., additional, Rosenberg, Jonathan E., additional, Safonov, Anton, additional, Shoushtari, Alexander N., additional, Tap, William, additional, Teo, Min Yuen, additional, Varghese, Anna M., additional, Voss, Martin, additional, Yaeger, Rona, additional, Zauderer, Marjorie G., additional, Abu-Rustum, Nadeem, additional, Garcia-Aguilar, Julio, additional, Bochner, Bernard, additional, Hakimi, Abraham, additional, Jarnagin, William R., additional, Jones, David R., additional, Molena, Daniela, additional, Morris, Luc, additional, Rios-Doria, Eric, additional, Russo, Paul, additional, Singer, Samuel, additional, Strong, Vivian E., additional, Chakravarty, Debyani, additional, Ellenson, Lora H., additional, Gopalan, Anuradha, additional, Reis-Filho, Jorge S., additional, Weigelt, Britta, additional, Ladanyi, Marc, additional, Gonen, Mithat, additional, Shah, Sohrab P., additional, Massague, Joan, additional, Gao, Jianjiong, additional, Zehir, Ahmet, additional, Berger, Michael F., additional, Solit, David B., additional, Bakhoum, Samuel F., additional, Sanchez-Vega, Francisco, additional, and Schultz, Nikolaus, additional

Published
2021
Full Text
View/download PDF

97. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Author

Kim, Dae-Hwan, primary, Sun, Duanchen, additional, Storck, William K., additional, Welker Leng, Katherine, additional, Jenkins, Chelsea, additional, Coleman, Daniel J., additional, Sampson, David, additional, Guan, Xiangnan, additional, Kumaraswamy, Anbarasu, additional, Rodansky, Eva S., additional, Urrutia, Joshua A., additional, Schwartzman, Jacob A., additional, Zhang, Chao, additional, Beltran, Himisha, additional, Labrecque, Mark P., additional, Morrissey, Colm, additional, Lucas, Jared M., additional, Coleman, Ilsa M., additional, Nelson, Peter S., additional, Corey, Eva, additional, Handelman, Samuel K., additional, Sexton, Jonathan Z., additional, Aggarwal, Rahul, additional, Abida, Wassim, additional, Feng, Felix Y., additional, Small, Eric J., additional, Spratt, Daniel E., additional, Bankhead, Armand, additional, Rao, Arvind, additional, Gesner, Emily M., additional, Attwell, Sarah, additional, Lakhotia, Sanjay, additional, Campeau, Eric, additional, Yates, Joel A., additional, Xia, Zheng, additional, and Alumkal, Joshi J., additional

Published
2021
Full Text
View/download PDF

98. CD38 in Advanced Prostate Cancers

Author

Guo, Christina, primary, Crespo, Mateus, additional, Gurel, Bora, additional, Dolling, David, additional, Rekowski, Jan, additional, Sharp, Adam, additional, Petremolo, Antonella, additional, Sumanasuriya, Semini, additional, Rodrigues, Daniel N., additional, Ferreira, Ana, additional, Pereira, Rita, additional, Figueiredo, Ines, additional, Mehra, Niven, additional, Lambros, Maryou B.K., additional, Neeb, Antje, additional, Gil, Veronica, additional, Seed, George, additional, Terstappen, Leon, additional, Alimonti, Andrea, additional, Drake, Charles G., additional, Yuan, Wei, additional, de Bono, Johann S., additional, Robinson, Dan, additional, Van Allen, Eliezer M., additional, Wu, Yi-Mi, additional, Schultz, Nikolaus, additional, Lonigro, Robert J., additional, Mosquera, Juan-Miguel, additional, Montgomery, Bruce, additional, Taplin, Mary-Ellen, additional, Pritchard, Colin C., additional, Attard, Gerhardt, additional, Beltran, Himisha, additional, Abida, Wassim, additional, Bradley, Robert K., additional, Vinson, Jake, additional, Cao, Xuhong, additional, Vats, Pankaj, additional, Kunju, Lakshmi P., additional, Hussain, Maha, additional, Tomlins, Scott A., additional, Cooney, Kathleen A., additional, Smith, David C., additional, Brennan, Christine, additional, Siddiqui, Javed, additional, Mehra, Rohit, additional, Chen, Yu, additional, Rathkopf, Dana E., additional, Morris, Michael J., additional, Solomon, Stephen B., additional, Durack, Jeremy C., additional, Reuter, Victor E., additional, Gopalan, Anuradha, additional, Gao, Jianjiong, additional, Loda, Massimo, additional, Lis, Rosina T., additional, Bowden, Michaela, additional, Balk, Stephen P., additional, Gaviola, Glenn, additional, Sougnez, Carrie, additional, Gupta, Manaswi, additional, Yu, Evan Y., additional, Mostaghel, Elahe A., additional, Cheng, Heather H., additional, Mulcahy, Hyojeong, additional, True, Lawrence D., additional, Plymate, Stephen R., additional, Dvinge, Heidi, additional, Ferraldeschi, Roberta, additional, Flohr, Penny, additional, Miranda, Susana, additional, Zafeiriou, Zafeiris, additional, Tunariu, Nina, additional, Mateo, Joaquin, additional, Perez-Lopez, Raquel, additional, Demichelis, Francesca, additional, Robinson, Brian D., additional, Schiffman, Marc, additional, Nanus, David M., additional, Tagawa, Scott T., additional, Sigaras, Alexandros, additional, Eng, Kenneth W., additional, Elemento, Olivier, additional, Sboner, Andrea, additional, Heath, Elisabeth I., additional, Scher, Howard I., additional, Pienta, Kenneth J., additional, Kantoff, Philip, additional, Rubin, Mark A., additional, Nelson, Peter S., additional, Garraway, Levi A., additional, Sawyers, Charles L., additional, and Chinnaiyan, Arul M., additional

Published
2021
Full Text
View/download PDF

99. Additional file 2 of Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Author

Tsui, Dana W. Y., Cheng, Michael L., Shady, Maha, Yang, Julie L., Stephens, Dennis, Won, Helen, Srinivasan, Preethi, Huberman, Kety, Meng, Fanli, Jing, Xiaohong, Patel, Juber, Hasan, Maysun, Johnson, Ian, Gedvilaite, Erika, Houck-Loomis, Brian, Socci, Nicholas D., Selcuklu, S. Duygu, Seshan, Venkatraman E., Zhang, Hongxin, Chakravarty, Debyani, Zehir, Ahmet, Benayed, Ryma, Arcila, Maria, Ladanyi, Marc, Funt, Samuel A., Feldman, Darren R., Li, Bob T., Razavi, Pedram, Rosenberg, Jonathan, Bajorin, Dean, Iyer, Gopa, Abida, Wassim, Scher, Howard I., Rathkopf, Dana, Viale, Agnes, Berger, Michael F., and Solit, David B.

Abstract

Additional file 2: Fig. S1. Summary of the cell-free DNA (cfDNA) profiling assays and number of samples involved in the study. Fig. S2. Evaluation of the tumor fraction estimate determined by ichorCNA in cfDNA of healthy controls and cancer patients. Fig. S3. Distribution of genome-wide z-scores in patients with and without mutations detected by cfMSK-IPMACT. Fig. S4. Comparison of proportion of tumor mutations detected in plasma with z-scores ≥5 and

Published
2021
Full Text
View/download PDF

100. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Author

Loehr, Andrea, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Hussain, Arif, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Abida, Wassim, Loehr, Andrea, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Hussain, Arif, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, and Abida, Wassim

Abstract

Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA(+)), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report dinical efficacy in patients with BRCA(+) mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2. Patients and Methods: Patients had progressed after next-generation androgen receptor-directed and taxane-based therapies for mCRPC and had BRCA alterations identified by central sequencing of plasma and/or tissue samples or local genomic testing. Concordance of plasma/tissue BRCA status and objective response rate and prostate-specific antigen (PSA) response rates were summarized. Results: TRITON2 enrolled 115 patients with BRCA(+) identified by central plasma (n = 34), central tissue (n = 37), or local (n = 44) testing. Plasma/tissue concordance was determined in 38 patients with paired samples and was 47% in 19 patients with a somatic BRCA alteration. No statistically significant differences were observed between objective and PSA response rates to rucaparib across the 3 assay groups. Patients unable to provide tissue samples and tested solely by plasma assay responded at rates no different from patients identified as BRCA(+) by tissue testing. Conclusions: Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA(+) mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results